Title |
Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men
|
---|---|
Published in |
PLOS ONE, March 2014
|
DOI | 10.1371/journal.pone.0091513 |
Pubmed ID | |
Authors |
Julia L. Marcus, David V. Glidden, Vanessa McMahan, Javier R. Lama, Kenneth H. Mayer, Albert Y. Liu, Orlando Montoya-Herrera, Martin Casapia, Brenda Hoagland, Robert M. Grant |
Abstract |
In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study. We examined the effect of daily oral emtricitabine/tenofovir (FTC/TDF) PrEP on HSV-2 seroincidence and ulcer occurrence among men who have sex with men (MSM) in the iPrEx trial. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
Brazil | 2 | 3% |
Unknown | 76 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 15% |
Student > Master | 12 | 15% |
Professor | 8 | 10% |
Student > Bachelor | 8 | 10% |
Other | 5 | 6% |
Other | 16 | 20% |
Unknown | 19 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 33% |
Nursing and Health Professions | 4 | 5% |
Social Sciences | 4 | 5% |
Psychology | 4 | 5% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 13 | 16% |
Unknown | 26 | 33% |